TAK-881
TAK-881-3002
Phase 3 small_molecule active
Quick answer
TAK-881 for Primary Immunodeficiency Diseases is a Phase 3 program (small_molecule) at Baxalta Innovations GmbH with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Baxalta Innovations GmbH
- Indication
- Primary Immunodeficiency Diseases
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active